261 related articles for article (PubMed ID: 21297370)
1. [Genetic marker of statin-induced rhabdomyolysis].
Chiba K; Morimoto K
Yakugaku Zasshi; 2011 Feb; 131(2):247-53. PubMed ID: 21297370
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction.
Marusic S; Lisicic A; Horvatic I; Bacic-Vrca V; Bozina N
Int J Clin Pharm; 2012 Dec; 34(6):825-7. PubMed ID: 23076661
[TBL] [Abstract][Full Text] [Related]
3. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
[TBL] [Abstract][Full Text] [Related]
4. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2.
Ferrari M; Guasti L; Maresca A; Mirabile M; Contini S; Grandi AM; Marino F; Cosentino M
Eur J Clin Pharmacol; 2014 May; 70(5):539-47. PubMed ID: 24595600
[TBL] [Abstract][Full Text] [Related]
5. Cerivastatin, genetic variants, and the risk of rhabdomyolysis.
Marciante KD; Durda JP; Heckbert SR; Lumley T; Rice K; McKnight B; Totah RA; Tamraz B; Kroetz DL; Fukushima H; Kaspera R; Bis JC; Glazer NL; Li G; Austin TR; Taylor KD; Rotter JI; Jaquish CE; Kwok PY; Tracy RP; Psaty BM
Pharmacogenet Genomics; 2011 May; 21(5):280-8. PubMed ID: 21386754
[TBL] [Abstract][Full Text] [Related]
6. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.
Canestaro WJ; Austin MA; Thummel KE
Genet Med; 2014 Nov; 16(11):810-9. PubMed ID: 24810685
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
[TBL] [Abstract][Full Text] [Related]
8. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
[TBL] [Abstract][Full Text] [Related]
9. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
10. The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
Voora D; Shah SH; Spasojevic I; Ali S; Reed CR; Salisbury BA; Ginsburg GS
J Am Coll Cardiol; 2009 Oct; 54(17):1609-16. PubMed ID: 19833260
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
[TBL] [Abstract][Full Text] [Related]
12. Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
Lönnberg KI; Tornio A; Hirvensalo P; Keskitalo J; Mustaniemi AL; Kiiski JI; Filppula AM; Niemi M
Pharmacogenet Genomics; 2023 Sep; 33(7):153-160. PubMed ID: 37490620
[TBL] [Abstract][Full Text] [Related]
13. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
[TBL] [Abstract][Full Text] [Related]
14. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
[TBL] [Abstract][Full Text] [Related]
15. Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies.
Hou Q; Li S; Li L; Li Y; Sun X; Tian H
Medicine (Baltimore); 2015 Sep; 94(37):e1268. PubMed ID: 26376374
[TBL] [Abstract][Full Text] [Related]
16. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
Cooper-DeHoff RM; Niemi M; Ramsey LB; Luzum JA; Tarkiainen EK; Straka RJ; Gong L; Tuteja S; Wilke RA; Wadelius M; Larson EA; Roden DM; Klein TE; Yee SW; Krauss RM; Turner RM; Palaniappan L; Gaedigk A; Giacomini KM; Caudle KE; Voora D
Clin Pharmacol Ther; 2022 May; 111(5):1007-1021. PubMed ID: 35152405
[TBL] [Abstract][Full Text] [Related]
17. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink.
Carr DF; O'Meara H; Jorgensen AL; Campbell J; Hobbs M; McCann G; van Staa T; Pirmohamed M
Clin Pharmacol Ther; 2013 Dec; 94(6):695-701. PubMed ID: 23942138
[TBL] [Abstract][Full Text] [Related]
18. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
[TBL] [Abstract][Full Text] [Related]
19. Researchers worry about myopathy risk for patients taking high-dose simvastatin.
Mitka M
JAMA; 2009 Jan; 301(3):261-2. PubMed ID: 19155447
[No Abstract] [Full Text] [Related]
20. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
Generaux GT; Bonomo FM; Johnson M; Doan KM
Xenobiotica; 2011 Aug; 41(8):639-51. PubMed ID: 21425956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
